Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis

Table 1

Baseline characterization of included literatures.

Author and year	Case load; (T/C)	Gender; (male/female)	Age; (T/C, year)	Intervening measure	Time (w)	Outcome	Random method
Yu Xia 2020 [9]	60/60	61/59		C: mesalazine; T: mesalazine+VD	8	①②④	—
Senyuan Zheng 2021 [10]	52/51	51/52		C: mesalazine; T: mesalazine+VD	8	①②	—
Haipeng Dou 2021 [11]	44/44	58/30		C: sulfasalazine; T: sulfasalazine+VD	4	①③④⑧	Random number table
Ningning Yue 2020 [8]	40/40	38/44		C: mesalazine+placebo; T: mesalazine+VD	8	①②⑤; ⑥⑦⑧	Computer stochastic method
Hongliang Gao 2021 [12]	57/59	59/57		C: mesalazine; T: mesalazine+VD	24	①⑥⑨	—
Fenghui Chen 2018 [13]	40/42	44/38		C: mesalazine; T: mesalazine+VD	6	①②③④	Random number table
Rong Yang 2017 [15]	40/40	51/39		C: mesalazine; T: mesalazine+VD	12	①	—
Yang Jing 2019 [14]	99/99	104/94		C: mesalazine; T: mesalazine+VD	4	④⑤⑥⑦	—
Shusheng Zhu 2015 [16]	60/60	60/60		C: mesalazine; T: mesalazine+VD	4	①⑧	—
Vahedi 2016 [17]	45/45	49/41		C: mesalazine+NS; T: mesalazine+VD	6	⑥	Random number table

T: treatment group; C: control group. Clinical observation indicators: ①—effective rate, ②—Mayo risk score, ③—serum MDA, ④—serum DAO, ⑤—IL-6, ⑥—CRP, ⑦—TNF-α, and ⑧—incidence of adverse reactions.